PARP-话题@MedSci

#PARP#

95篇内容 | 2767人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621337, encodeId=a237162133ef1, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌, objectType=article, longId=172198, objectId=d2b91e21983c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2b91e21983c, replyNumber=0, likeNumber=62, createdTime=2019-06-27, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2b91e21983c, moduleTitle=欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2b91e21983c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621336, encodeId=ca0e1621336dd, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, objectType=article, longId=167750, objectId=63b216e750f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b216e750f8, replyNumber=0, likeNumber=95, createdTime=2019-06-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b216e750f8, moduleTitle=2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63b216e750f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621335, encodeId=baf41621335fa, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, objectType=article, longId=167610, objectId=0be116e61073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be116e61073, replyNumber=0, likeNumber=66, createdTime=2019-06-05, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be116e61073, moduleTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be116e61073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621334, encodeId=6bdc162133476, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌, objectType=article, longId=164061, objectId=5ae5164061d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ae5164061d3, replyNumber=0, likeNumber=104, createdTime=2019-04-12, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ae5164061d3, moduleTitle=阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ae5164061d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621333, encodeId=5fd61621333ba, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, objectType=article, longId=161224, objectId=fd561612244e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd561612244e, replyNumber=0, likeNumber=56, createdTime=2019-02-28, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd561612244e, moduleTitle=AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd561612244e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621332, encodeId=e82c162133235, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？, objectType=article, longId=157547, objectId=091815e54770, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091815e54770, replyNumber=0, likeNumber=63, createdTime=2019-01-09, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091815e54770, moduleTitle=JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091815e54770)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621331, encodeId=a41e1621331df, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=百济神州PARP抑制剂获十三五“国家重大新药创制专项”立项支持, objectType=article, longId=156857, objectId=480315685eeb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480315685eeb, replyNumber=0, likeNumber=96, createdTime=2018-12-29, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480315685eeb, moduleTitle=百济神州PARP抑制剂获十三五“国家重大新药创制专项”立项支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480315685eeb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621330, encodeId=d157162133099, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=百济神州公布PARP抑制剂pamiparib的初步临床数据, objectType=article, longId=153822, objectId=ef4b153822c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef4b153822c9, replyNumber=0, likeNumber=120, createdTime=2018-11-19, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef4b153822c9, moduleTitle=百济神州公布PARP抑制剂pamiparib的初步临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef4b153822c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621329, encodeId=db1b16213298e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用, objectType=article, longId=153276, objectId=77c61532e65e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c61532e65e, replyNumber=0, likeNumber=63, createdTime=2018-11-13, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c61532e65e, moduleTitle=NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c61532e65e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621328, encodeId=3dcf162132873, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=百济神州将公布PARP抑制剂Pamiparib的临床数据, objectType=article, longId=152848, objectId=40701528481c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40701528481c, replyNumber=0, likeNumber=85, createdTime=2018-11-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40701528481c, moduleTitle=百济神州将公布PARP抑制剂Pamiparib的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40701528481c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621327, encodeId=f8fd162132e7a, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP抑制剂治疗复发性卵巢癌专家共识, objectType=article, longId=151855, objectId=647a151855af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=647a151855af, replyNumber=0, likeNumber=28, createdTime=2018-10-26, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=647a151855af, moduleTitle=PARP抑制剂治疗复发性卵巢癌专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=647a151855af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621326, encodeId=5aee162132665, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=辉瑞公司在美国欧盟申请PARP抑制剂治疗乳腺癌, objectType=article, longId=140469, objectId=c2e5140469f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e5140469f7, replyNumber=0, likeNumber=27, createdTime=2018-06-12, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e5140469f7, moduleTitle=辉瑞公司在美国欧盟申请PARP抑制剂治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e5140469f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621325, encodeId=4ddd1621325af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, objectType=article, longId=138866, objectId=681b1388668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681b1388668c, replyNumber=0, likeNumber=40, createdTime=2018-05-24, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681b1388668c, moduleTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681b1388668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621324, encodeId=c9e51621324d5, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=科学家发现导致PARP抑制剂抗性的突变, objectType=article, longId=138013, objectId=0cc313801384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cc313801384, replyNumber=0, likeNumber=62, createdTime=2018-05-14, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cc313801384, moduleTitle=科学家发现导致PARP抑制剂抗性的突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cc313801384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621323, encodeId=bd6316213236f, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, objectType=article, longId=134828, objectId=ba40134828dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba40134828dd, replyNumber=0, likeNumber=65, createdTime=2018-04-12, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba40134828dd, moduleTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba40134828dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化, objectType=article, longId=130548, objectId=c36d130548fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c36d130548fe, replyNumber=0, likeNumber=58, createdTime=2018-02-23, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c36d130548fe, moduleTitle=Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c36d130548fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621321, encodeId=97161621321a5, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, objectType=article, longId=123424, objectId=07e11234248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07e11234248f, replyNumber=0, likeNumber=66, createdTime=2017-12-16, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07e11234248f, moduleTitle=Matulonis教授：PARP抑制剂——BRCA相关癌症的克星, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07e11234248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621320, encodeId=35d01621320f5, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=C&EN：癌症新药PARP抑制剂获批，完美利用癌细胞弱点，粉碎它们的基因！, objectType=article, longId=115940, objectId=d18b11594001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d18b11594001, replyNumber=0, likeNumber=60, createdTime=2017-10-14, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d18b11594001, moduleTitle=C&EN：癌症新药PARP抑制剂获批，完美利用癌细胞弱点，粉碎它们的基因！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d18b11594001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621319, encodeId=5767162131996, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展, objectType=article, longId=113966, objectId=398e11396633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=398e11396633, replyNumber=0, likeNumber=0, createdTime=2017-09-25, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=398e11396633, moduleTitle=ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=398e11396633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621318, encodeId=1e8a162131821, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采, objectType=article, longId=112977, objectId=a4831129e7a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4831129e7a8, replyNumber=0, likeNumber=93, createdTime=2017-09-17, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4831129e7a8, moduleTitle=ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4831129e7a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP

2020-05-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

欧盟批准辉瑞的PARP抑制剂Talzenna，用于治疗BRCA突变的乳腺癌

2019-06-27

lishiwen (审核中...)

前往app查看评论内容

#PARP#

2019 ASCO：AZ/MSD的PARP抑制剂Lynparza再创佳绩，晚期卵巢癌效果显着

2019-06-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色

2019-06-05

lishiwen (审核中...)

前往app查看评论内容

#PARP#

阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌

2019-04-12

lishiwen (审核中...)

前往app查看评论内容

#PARP#

AZ和MSD的药物PARP抑制剂Lynparza在BRCA突变的胰腺癌中大获成功

2019-02-28

lishiwen (审核中...)

前往app查看评论内容

#PARP#

JCO：PARP抑制剂veliparib进军广泛期小细胞肺癌一线，小细胞肺癌又多了一种治疗方式？

2019-01-09

lishiwen (审核中...)

前往app查看评论内容

#PARP#

百济神州PARP抑制剂获十三五“国家重大新药创制专项”立项支持

2018-12-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

百济神州公布PARP抑制剂pamiparib的初步临床数据

2018-11-19

lishiwen (审核中...)

前往app查看评论内容

#PARP#

NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用

2018-11-13

lishiwen (审核中...)

前往app查看评论内容

#PARP#

百济神州将公布PARP抑制剂Pamiparib的临床数据

2018-11-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP抑制剂治疗复发性卵巢癌专家共识

2018-10-26

lishiwen (审核中...)

前往app查看评论内容

#PARP#

辉瑞公司在美国欧盟申请PARP抑制剂治疗乳腺癌

2018-06-12

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感

2018-05-24

lishiwen (审核中...)

前往app查看评论内容

#PARP#

科学家发现导致PARP抑制剂抗性的突变

2018-05-14

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗

2018-04-12

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化

2018-02-23

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Matulonis教授：PARP抑制剂——BRCA相关癌症的克星

2017-12-16

lishiwen (审核中...)

前往app查看评论内容

#PARP#

C&EN：癌症新药PARP抑制剂获批，完美利用癌细胞弱点，粉碎它们的基因！

2017-10-14

lishiwen (审核中...)

前往app查看评论内容

#PARP#

ESMO:吴鸣教授：卵巢癌PARPi维持治疗进展

2017-09-25

lishiwen (审核中...)

前往app查看评论内容

#PARP#

ESMO热点追踪之乳乳腺癌再启征程——PARP抑制剂展风采

2017-09-17

科室
- - 订阅+
  - 更多科室
工具
服务